Placental Growth Hormone (GH), GH-Binding Protein, and Insulin-Like Growth Factor Axis in Normal, Growth-Retarded, and Diabetic Pregnancies: Correlations with Fetal Growth*

McIntyre, H. David; Serek, R.; Crane, Denis I.; Veveris-Lowe, Tara; Parry, Annette F; Johnson, Sandra Marchese; Leung, Kin‐Chuen; Ho, Ken K. Y.; Bougoussa, M.; Hennen, Georges; Igout, Ahmed; Chan, Felix Hon-Wai; Cowley, David; Cotterill, A M; Barnard, Ross

doi:10.1210/jcem.85.3.6480

Cited by 67 publications

(34 citation statements)

References 40 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…[18][19][20][21] We found that serum IGF-I concentrations in maternal blood at delivery (36 weeks) were significantly higher than at 28 weeks of gestation in both groups, with concentrations being higher in the diabetic group than the control group. In our six cases of neonatal septal hypertrophic cardiomyopathy, all the mothers had very high IGF-I concentrations of more than 400 ng/ml at the time of delivery, compared with a mean (SD) of 302 (25) ng/ml in control mothers.…”

Section: Discussionmentioning

confidence: 66%

The role of serum insulin-like growth factor I (IGF-I) in neonatal outcome

Hayati

2004

J Clin Pathol

View full text Add to dashboard Cite

Aims: To determine the role of serum insulin-like growth factor I (IGF-I) in predicting the occurrence of septal hypertrophic cardiomyopathy in infants of mothers with diabetes. Methods/materials: In this prospective study, 100 pregnant women (50 with diabetes and 50 controls), matched for age and race, were studied. One intrapartum blood sample was taken at 28 weeks of gestation from both groups of mothers and another sample at delivery. All samples were analysed for maternal IGF-I by an enzyme linked immunosorbent assay method. A chest radiograph and an electrocardiogram were performed on the babies of the mothers with diabetes within the first 24 hours of life. An echocardiogram was performed in the first 3 days of life to look for septal hypertrophy and to measure the myocardial thickness. Results: In the six cases of neonatal septal hypertrophic cardiomyopathy, all the mothers had greatly raised IGF-I concentrations of more than 400 ng/ml at the time of delivery compared with a mean (SD) of 302 (25) ng/ml in control mothers. Conclusions: In the present study a crude analysis revealed that increased IGF-I concentrations correlate with neonatal septal hypertrophic cardiomyopathy.

show abstract

Section: Discussionmentioning

confidence: 66%

The role of serum insulin-like growth factor I (IGF-I) in neonatal outcome

Hayati

2004

J Clin Pathol

View full text Add to dashboard Cite

show abstract

“…IGFBP-1 limits the availability of free IGF-I in the fetus. It is regulated by intracellular glucose and insulin (16), and inhibits the growth promoting effects of IGF-1 and GH (18). Therefore, we were not surprised to find that positive correlations between birth weight and umbilical cord IGF-I, and negative correlations between birth weight, ponderal index, and umbilical cord IGFBP-I in the term untreated group.…”

Section: Discussionmentioning

confidence: 83%

“…IGFs circulate in the serum bound to IGF binding proteins (IGFBPs) and produce mitogenic effects by acting on IGF-I and insulin receptors (16). Studies have shown that low birth weight is associated with decreased IGF-I, IGF-II and IGFBP-3 and elevated level of IGFBP-1 (17)(18)(19). Although GH has minimal influence on fetal somatic growth due to a paucity of GH receptors, the fetus produces large amounts in late gestation and the IGF-GH axis appears to be functional in utero (20).…”

Section: Introductionmentioning

confidence: 99%

Influence of a single course of antenatal betamethasone on the maternal–fetal insulin-IGF-GH axis in singleton pregnancies

Ahmad

Beharry

Valencia

et al. 2006

Growth Hormone & IGF Research

View full text Add to dashboard Cite

Objective. We examined the hypothesis that a single course of antenatal betamethasone influences the maternal-fetal insulin-IGF-GH axis.Design. A prospective, observational, pilot study consisting of four groups of pregnant women: I) received betamethasone and delivered <2 weeks post treatment; II) received betamethasone and delivered >2 weeks post treatment; III) untreated women who delivered <37 weeks (preterm controls); IV) untreated women who delivered >37 weeks (term controls). Maternal and mixed umbilical cord blood was collected at delivery and analyzed for insulin, glucose, IGF-I, IGF-II, IGFBP-1, IGFBP-3, GH, GHBP.Results. Betamethasone increased maternal insulin, glucose and IGF-I levels without affecting IGFBPs. In the fetal compartment, betamethasone treatment was associated with a delayed suppressive effect on GH and a sustained suppressive effect on IGF-II levels. There were no differences in infant size or neonatal morbidities between patients who delivered <2 weeks or >2 weeks post betamethasone treatment. In Group IV, birth weight correlated positively with cord IGF-I levels (r2=0.41, p=0.0098) and negatively with cord IGFBP-1 levels (r2=0.51, p=0.0039), and ponderal index correlated negatively with cord IGFBP-1 levels (r2=0.27, p<0.05).Conclusions. A single course of antenatal betamethasone influences the maternal-fetal insulin-IGF-GH axis, particularly fetal IGF-II levels, without measurable anthropometric changes at birth. Whether these effects have implications beyond the neonatal period remains to be determined.Irfan Ahmad, MD 1 Running Title: Betamethasone and the insulin-IGF-GH axis. INFLUENCE OF A SINGLE COURSE OF ANTENATAL BETAMETHASONE ON THE MATERNAL-FETAL INSULIN-IGF-GH AXIS IN SINGLETON PREGNANCIES * ManuscriptIrfan Ahmad, MD 2 ABSTRACTObjective. We examined the hypothesis that a single course of antenatal betamethasone influences the maternal-fetal insulin-IGF-GH axis.Design. A prospective, observational, pilot study consisting of four groups of pregnant women:I) received betamethasone and delivered <2 weeks post treatment; II) received betamethasone and delivered >2 weeks post treatment; III) untreated women who delivered <37 weeks (preterm controls); IV) untreated women who delivered >37 weeks (term controls). Maternal and mixed umbilical cord blood was collected at delivery and analyzed for insulin, glucose, IGF-I, IGF-II, IGFBP-1, IGFBP-3, GH, GHBP. Results. Betamethasone increased maternal insulin, glucose and IGF-I levels without affectingIGFBPs. In the fetal compartment, betamethasone treatment was associated with a delayed suppressive effect on GH and a sustained suppressive effect on IGF-II levels. There were no differences in infant size or neonatal morbidities between patients who delivered <2 weeks or >2 weeks post betamethasone treatment. In Group IV, birth weight correlated positively with cord IGF-I levels (r 2 =0.41, p=0.0098) and negatively with cord IGFBP-1 levels (r 2 =0.51, p=0.0039), and ponderal index correlated negatively with cord IGFBP-1 levels (r...

show abstract

“…multiple pregnancies) do not present with higher levels of IGF-I early in pregnancy [22]. Both types of diabetes show a strong correlation with human placental growth hormone (hPGH) [30]. Moreover, maternal levels of serum IGF-I were similar in pregnancies with normal weight -, small-for-gestational-age -, and multiple neonates, respectively [22,24], whereas in diabetic pregnancy 'early growth delay' in first trimester has been associated with high IGF-I levels [14,28].…”

Section: Birth Weightmentioning

confidence: 99%

The Clinical Significance of IGF-I in Maternal Serum During Pregnancy in Type 1 Diabetes

Lauszus

2007

CDR

View full text Add to dashboard Cite

Insulin-like growth factors (IGFs) constitute a system of peptides that promote mitosis, growth, and organ development by both paracrine and endocrine pathways, their bioavailability being modulated by at least six specific IGF-binding proteins (IGFBP). In type 1 diabetic pregnancies IGF-I and -II in maternal serum are associated with birth weight and their action modulated by IGFBP-3 and phosphorylated isoforms of IGFBP-1. Pregnancy-associated plasma protein-A (PAPP-A), a proteolytic substance of IGFBPs, is probably a modulator in early diabetic pregnancy while human placental growth hormone (hPGH) regulates the effect of IGF-I in pregnancy of diabetic and non-diabetic pregnancies. IGF-I in maternal serum increases concomitantly with progression of diabetic retinopathy despite good glycemic control in pregnancy. The role of the new insulin analogues in improving this effect has yet to be established. Retinopathy in pregnancy is associated with an elevated level of fibroblast growth factor-2 (FGF-2) and highly-phosphorylated IGFBP-1, the latter further increasing the level of free IGF-I and FGF-2. Thus, the effect on development of retinopathy may be directly mediated by IGF-I or indirectly by a modifying effect of IGFBP-3 and phosphorylated isoforms of IGFBP-1 with FGF-2 as a mediator.

show abstract

Placental Growth Hormone (GH), GH-Binding Protein, and Insulin-Like Growth Factor Axis in Normal, Growth-Retarded, and Diabetic Pregnancies: Correlations with Fetal Growth*

Cited by 67 publications

References 40 publications

The role of serum insulin-like growth factor I (IGF-I) in neonatal outcome

The role of serum insulin-like growth factor I (IGF-I) in neonatal outcome

Influence of a single course of antenatal betamethasone on the maternal–fetal insulin-IGF-GH axis in singleton pregnancies

The Clinical Significance of IGF-I in Maternal Serum During Pregnancy in Type 1 Diabetes

Contact Info

Product

Resources

About